Streetbeat News

Price Targets

RCUS

HC Wainwright & Co. has reiterated a Neutral rating for Arcus Biosciences (NYSE:RCUS) and maintained a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 7:21 pm

RPTX

HC Wainwright & Co. has reiterated its Buy rating on Repare Therapeutics (NASDAQ:RPTX) and maintained a price target of $10.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 7:16 pm

PHAR

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Pharming (NASDAQ:PHAR) and maintained a price target of $37.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 7:14 pm

EEFT

Needham analyst Mayank Tandon maintains a Buy rating on Euronet Worldwide (NASDAQ:EEFT) but lowers the price target from $125 to $120.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 7:11 pm

ASML

LRCX

Analysts from BofA Securities and Goldman Sachs have reiterated Buy ratings for Lam Research (NASDAQ:LRCX), highlighting its growth potential amid a NAND recovery and advanced packaging strength. Despite risks from China and export controls, Lam Research is expected to outperform competitors in 2025 due to its unique portfolio and market share gains in wafer fabrication equipment.

Portfolio Pulse from Nabaparna Bhattacharya

October 24, 2024 | 7:09 pm

WING

Stephens & Co. analyst Jim Salera has reiterated an Overweight rating on Wingstop (NASDAQ:WING) and maintained a price target of $490.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 7:08 pm

VYGR

HC Wainwright & Co. has reiterated a Buy rating for Voyager Therapeutics with a maintained price target of $30.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 7:04 pm

PII

Polaris (NYSE:PII) has received mixed ratings from analysts over the past three months, with a recent decline in average price targets. Analysts have lowered their ratings and price targets, reflecting concerns over Polaris's recent revenue decline and high debt levels, despite strong net margins and returns on equity and assets.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 7:01 pm

GL

Over the past three months, 7 analysts have evaluated Globe Life (NYSE:GL), with a mix of bullish and indifferent ratings. The average 12-month price target has increased by 16.1% to $127.71. Analysts have raised their ratings and price targets, reflecting positive sentiment towards Globe Life's financial performance, including strong revenue growth, net margin, and return on equity.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 7:00 pm

MXL

Analysts have varied opinions on MaxLinear (NASDAQ:MXL), with recent ratings showing a shift towards bullish sentiment. The average 12-month price target has decreased by 18.4% to $20.67. MaxLinear faces financial challenges, including a significant revenue decline and low profitability metrics.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 7:00 pm